glp 1 agonist natural Mapping the effectiveness and risks of GLP-1 receptor agonists Evolution of GLP‐1 Receptor Agonists

Description

This high rate of disruption in medication adherence underscores a need to further explore factors influencing medication adherence and identify supportive measures to enhance long-term outcomes

Feb.-April 2022 and 2023

192207 While concerns about potential muscle loss with GLP-1 RAs remain, recent evidence from the SEMALEAN study suggests this risk may be attenuated with semaglutide 2.4 mg

This means survodutide may provide additional benefits for fat loss specifically, particularly visceral and liver fat, beyond what GIP/GLP-1 dual agonism achieves

Systematic meta-analyses have established that sulfonylurea therapy shows no protective effect against prostate cancer development in patients with diabetes mellitus [102]